← Leaderboards
Warren A Chow
City Of Hope/Beckman Research Institute
$553,926
Attributed
$553,926
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $253.5K · FY2005–09$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
Funding mix
By agency
FDA$487,973 · 1
NIH$65,953 · 4
By mechanism
R01$487,973 · 1
M01$65,953 · 4
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Resources”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Heimbrook · Leidos Biomedical Research, Inc.$688,986,350
- Bambra Strokes · Ppd Development Lp$526,656,217
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Eric S Lander · Whitehead Institute For Biomedical Res$341,717,134
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$311,514,701
Research focus
ResourcesGrantFundingUnited States National Institutes Of HealthComputer Retrieval Of Information On Scientific Projects DatabaseResearch PersonnelSourceInstitutionLaboratoriesLiposarcomaAdipocytesGene TargetingAffectBaseMaximum Tolerated DoseInsulin ResistanceApoptoticHyperlipidemiaAdipose TissueFatty Acid Glycerol EstersHiv-Associated Lipodystrophy SyndromeGene ExpressionDrug KineticsCytotoxic Agent
Grant awards (7)
A PHASE I/II STUDY OF NELFINAVIR IN LIPOSARCOMA$41,611
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: A PHASE 2, OPEN-LABEL EVALUATION OF THE SAFETY AND EFFICACY OF C$1,158
M01 · FY2009 · RR · contact PI
A PHASE I/II STUDY OF NELFINAVIR IN LIPOSARCOMA$9,615
M01 · FY2008 · RR · contact PI
Phase 1/2 Study of Nelfinavir in Liposarcoma$234,473
R01 · FY2007 · FD · contact PI
A PHASE I/II STUDY OF NELFINAVIR IN LIPOSARCOMA$13,569
M01 · FY2007 · RR · contact PI
Phase 1/2 Study of Nelfinavir in Liposarcoma$253,500
R01 · FY2006 · FD · contact PI
Phase 1/2 Study of Nelfinavir in Liposarcoma$0
R01 · FY2005 · FD